EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy






Clinical Therapeutics 33(9): 1281-1288

Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy

Studies have examined adherence when switching from loose-dose combination therapy (LDCT) to fixed-dose combination therapy (FDCT) among oral antidiabetic agents. However, little is known regarding combination therapies, including pioglitazone and metformin. The objectives of this study were (1) to describe adherence to monotherapy (MT), LDCT, and FDCT of oral diabetic agents containing pioglitazone and metformin; to determine whether there are differences in the medication adherence of patients switching from MT or LDCT to the corresponding FDCT, while controlling for covariates; and to determine whether there are differences in medication costs between LDCT and the analogous FDCT. This retrospective database.


Accession: 036177583

PMID: 21840054

DOI: 10.1016/j.clinthera.2011.07.016



Related references

Melikian, C.; White, T.J.ffrey; Vanderplas, A.; Dezii, C.M.; Chang, E., 2002: Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Background: Although medication adherence is one of the most important aspects of the management of diabetes mellitus, low rates of adherence have been documented. Objective: This study sought to examine medication adherence among patients with di...

Melikian, C.; White, T.Jeffrey.; Vanderplas, A.; Dezii, C.M.; Chang, E., 2002: Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Although medication adherence is one of the most important aspects of the management of diabetes mellitus, low rates of adherence have been documented. This study sought to examine medication adherence among patients with diabetes mellitus in a ma...

Perez, A.; Zhao, Z.; Jacks, R.; Spanheimer, R., 2010: Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Studies have shown that many patients with type 2 diabetes do not achieve optimal glycemic control, and progression of diabetes over time requires more than one pharmacotherapy to achieve glycemic goal. To examine the efficacy and safety of the fi...

Perez, A.; Jacks, R.; Arora, V.; Spanheimer, R., 2011: Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. . Type 2 diabetes mellitus (T2DM) treatment should not increase cardiovascular (CV) risk and at best could provide benefit beyond lowering glucose. Pioglitazone has demonstrated a favorable CV profile relative to other oral antidiabetic drugs (OAD...

Karim, A.; Slater, M.; Bradford, D.; Schwartz, L.; Laurent, A., 2006: Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. An open-label, randomized, crossover study involving 28 healthy subjects was conducted to compare the peak (C-max) and total (AUC(lqc), AUC(infinity)) exposures to pioglitazone and metformin after single-dose administration of a fixed-dose combin...

Williams, S.A.; Buysman, E.K.; Hulbert, E.M.; Bergeson, J.Gdovin.; Zhang, B.; Graham, J., 2012: Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. To compare outcomes of type 2 diabetes mellitus (T2DM) patients initiating therapy with FDC vs. those with loose-dose combination (LDC) or step therapy (ST) in a managed care population. A retrospective claims database analysis. Treatment-naive T2...

Anonymous, 2011: Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. To evaluate the efficacy and safety of initial therapy with a fixed-dose combination of sitagliptin and metformin compared with pioglitazone in drug-na ve patients with type 2 diabetes.After a 2-week single-blind placebo run-in period, patients wi...

Wainstein, J.; Katz, L.; Engel, S.S.; Xu, L.; Golm, G.T.; Hussain, S.; O'Neill, E.A.; Kaufman, K.D.; Goldstein, B.J., 2012: Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. To evaluate the efficacy and safety of initial therapy with a fixed-dose combination (FDC) of sitagliptin and metformin compared with pioglitazone in drug-na ve patients with type 2 diabetes. : After a 2-week single-blind placebo run-in period, pa...

Lokhandwala, T.; Smith, N.; Sternhufvud, C.; Sörstadius, E.; Lee, W.Chan.; Mukherjee, J., 2015: A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. To compare outcomes between patients with type 2 diabetes mellitus (T2DM) using fixed-dose combination (FDC) and loose-dose combination (LDC) products. This retrospective cohort study used MarketScan Commercial and Medicare Supplemental data from...

Comaschi, M.; Corsi, A.; D.P.etro, C.; Bellatreccia, A.; Mariz, S.; Alessi; Baldini; Bevilacqua; Borzi; Cabasino; Calcaterra; Carducci; Cernigoi; Chiavetta; Chiovat; Cicioni; Cignarelli; Corda; Cordera; Corsi; D.R.va; D.P.etro; Donadon; Fellin; Fogari; Francesconi; Fugazza; Ghigo; Leotta; Mainini; Maolo; Marchesi; Marin; Marini; Masotti; Muscogiuri; Orio; Provenzano; Riccardi; Rognoni; Rossini; Serra; Tatti; Trevisan; Tuccinardi; Venezia, 2007: The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. Diabetic dyslipidaemia contributes to the increased risk of cardiovascular disease in patients with Type 2 diabetes. This paper examines the effectiveness of adding pioglitazone to metformin or a sulphonylurea (SU) compared with a fixed-dose combi...